Association of lipoprotein-associated phospholipase A2 and endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA)

Vascular Medicine

Volumn 16, Issue 4, 2011, Pages 247-252

  Garg, Parveen K ^a   McClelland, Robyn L ^b   Jenny, Nancy S ^c   Criqui, Michael ^d   Liu, Kiang ^a   Polak, Joseph F ^e   Jorgensen, Neal W ^b   Cushman, Mary ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TUFTS MEDICAL CENTER   (United States)

Author keywords

ankle brachial index; atherosclerosis; carotid intimal medial thickness; endothelial function; Lp PLA2

Indexed keywords

LIPOPROTEIN; PHOSPHOLIPASE A2;

ADULT; ANKLE BRACHIAL INDEX; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CAROTID ARTERY; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTHELIUM; FEMALE; FLOW MEASUREMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VASODILATATION;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; AGED, 80 AND OVER; ANKLE BRACHIAL INDEX; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BRACHIAL ARTERY; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LINEAR MODELS; MALE; MIDDLE AGED; PHOSPHOLIPASES A2; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOMETRY; RISK ASSESSMENT; RISK FACTORS; UNITED STATES; VASODILATION;

EID: 80051636445     PISSN: 1358863X     EISSN: 14770377     Source Type: Journal    
DOI: 10.1177/1358863X11411360     Document Type: Article

References (24)

1. Macphee C, Benson GM, Shi Y, Zalewski A. Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opin Investig Drugs. 2005 ; 14: 671-679 (Pubitemid 40895193)
2. MacPhee CH, Moores KE, Boyd HF, et al. Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor. Biochem J. 1999 ; 338 (Pt 2). 479-487
3. Kume N, Cybulsky MI, Gimbrone MA. Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest. 1992 ; 90: 1138-1144
4. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988 ; 85: 2805-2809
5. Murugesan G, Sandhya Rani MR, Gerber CE, et al. Lysophosphatidylcholine regulates human microvascular endothelial cell expression of chemokines. J Mol Cell Cardiol. 2003 ; 35: 1375-1384 (Pubitemid 37336565)
6. Wolfram Kuhlmann CR, Wiebke Ludders D, Schaefer CA, et al. Lysophosphatidylcholine-induced modulation of Ca(2+)-activated K(2+)channels contributes to ROS-dependent proliferation of cultured human endothelial cells. J Mol Cell Cardiol. 2004 ; 36: 675-682 (Pubitemid 38591600)
7. Chaudhuri P, Colles SM, Damron DS, Graham LM. Lysophosphatidylcholine inhibits endothelial cell migration by increasing intracellular calcium and activating calpain. Arterioscler Thromb Vasc Biol. 2003 ; 23: 218-223 (Pubitemid 36231931)
8. Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet. 2010 ; 375: 1536-1544
9. Yang EH, McConnell JP, Lennon RJ, et al. Lipoprotein-associated phospholipase A2 is an independent marker for coronary endothelial dysfunction in humans. Arterioscler Thromb Vasc Biol. 2006 ; 26: 106-111 (Pubitemid 43732235)
10. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation. 2009 ; 120: 502-509
11. Halcox JP, Donald AE, Ellins E, et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation. 2009 ; 119: 1005-1012
12. Harris LM, Faggioli GL, Shah R, et al. Vascular reactivity in patients with peripheral vascular disease. Am J Cardiol. 1995 ; 76: 207-212
13. Juonala M, Viikari JS, Laitinen T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation. 2004 ; 110: 2918-2923 (Pubitemid 39473618)
14. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: objectives and design. Am J Epidemiol. 2002 ; 156: 871-881 (Pubitemid 35215769)
15. Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol. 2006 ; 26: 631-636
16. Herrington DM, Fan L, Drum M, et al. Brachial flow- mediated vasodilator responses in population-based research: methods, reproducibility and effects of age, gender and baseline diameter. J Cardiovasc Risk. 2001 ; 8: 319-328 (Pubitemid 33010693)
17. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008 ; 300: 197-208 (Pubitemid 351969304)
18. Folsom AR, Kronmal RA, Detrano RC, et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2008 ; 168: 1333-1339 (Pubitemid 351930841)
19. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005 ; 111: 570-575 (Pubitemid 40216483)
20. Sabatine MS, Morrow DA, O'Donoghue M, et al. Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007 ; 27: 2463-2469 (Pubitemid 350203965)
21. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation. 2005 ; 111: 980-987 (Pubitemid 40354515)
22. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005 ; 26: 137-144 (Pubitemid 40282781)
23. Robins SJ, Collins D, Nelson JJ, Bloomfield HE, Asztalos BF. Cardiovascular events with increased lipoprotein- associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2008 ; 28: 1172-1178
24. Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia. Eur J Clin Invest. 1997 ; 27: 595-602 (Pubitemid 27320037)